Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza

• Verfasst von: Jäckel, Markus [VerfasserIn]
• Verfasst von: Rilinger, Jonathan [VerfasserIn]
• Verfasst von: Lang, Corinna Nadine [VerfasserIn]
• Verfasst von: Zotzmann, Viviane [VerfasserIn]
• Verfasst von: Kaier, Klaus [VerfasserIn]
• Verfasst von: Stachon, Peter [VerfasserIn]
• Verfasst von: Biever, Paul Marc [VerfasserIn]
• Verfasst von: Wengenmayer, Tobias [VerfasserIn]
• Verfasst von: Duerschmied, Daniel [VerfasserIn]
• Verfasst von: Bode, Christoph [VerfasserIn]
• Verfasst von: Staudacher, Dawid Leander [VerfasserIn]
• Verfasst von: Supady, Alexander [VerfasserIn]
• Titel: Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza
• Titelzusatz: a single-center registry study
• Verf.angabe: Markus Jäckel, Jonathan Rilinger, Corinna Nadine Lang, Viviane Zotzmann, Klaus Kaier, Peter Stachon, Paul Marc Biever, Tobias Wengenmayer, Daniel Duerschmied, Christoph Bode, Dawid Leander Staudacher, Alexander Supady
• E-Jahr: 2021
• Jahr: June 2021
• Umfang: 9 S.
• Fussnoten: First published: 14 November 2020 ; Gesehen am 04.01.2024
• Titel Quelle: Enthalten in: Artificial organs
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1977
• Jahr Quelle: 2021
• Band/Heft Quelle: 45(2021), 6, Seite 593-601
• ISSN Quelle: 1525-1594
• DOI: doi:10.1111/aor.13865
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: acute respiratory distress syndrome
• Sach-SW: coronavirus disease 2019
• Sach-SW: extracorporeal membrane oxygenation
• Sach-SW: influenza
• Sach-SW: severe acute respiratory syndrome coronavirus 2
• K10plus-PPN: 1877938998

Abstract

Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is used to sustain blood oxygenation and decarboxylation in severe acute respiratory distress syndrome (ARDS). It is under debate if V-V ECMO is as appropriate for coronavirus disease 2019 (Covid-19) ARDS as it is for influenza. In this retrospective study, we analyzed all patients with confirmed SARS-CoV-2 or influenza A/B infection, ARDS and V-V ECMO, treated at our medical intensive care unit (ICU) between October 2010 and June 2020. Baseline and procedural characteristics as well as survival 30 days after ECMO cannulation were analyzed. A total of 62 V-V ECMO patients were included (15 with Covid-19 and 47 with influenza). Both groups had similar baseline characteristics at cannulation. Thirty days after ECMO cannulation, 13.3% of all patients with Covid-19 were discharged alive from our ICU compared to 44.7% with influenza (P = .03). Patients with Covid-19 had fewer ECMO-free days (0 (0-9.7) days vs. 13.2 (0-22.1) days; P = .05). Cumulative incidences of 30-day-survival showed no significant differences (48.6% in Covid-19 patients, 63.7% in influenza patients; P = .23). ICU treatment duration was significantly longer in ARDS patients with V-V ECMO for Covid-19 compared to influenza. Thirty-day mortality was higher in Covid-19, but not significant.